Division Directors and Program Directors Conference

ACR Disclosure Statement
The ACR is an independent, professional organization that does not endorse specific procedures or products of any pharmaceutical/biotech concern. Educational activities provided by the ACR must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s). For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias.

Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience any financial or other relationship(s) including, but not limited to:

1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan
2. Research grants
3. Employment (full or part-time)
4. Ownership or partnership
5. Consulting fees or other remuneration (payment)
6. Non-remunerative positions of influence such as officer, board member, trustee, or public spokesperson
7. Receipt of royalties
8. Speakers' bureau
9. Other

The planning committee and faculty reported the following disclosures.

2019 Division Directors Conference Planning Committee Disclosures

• V. Michael Holers, MD - Stanford University (shared patent)⁷
• Joan M. Bathon, MD - Regeneron⁵
• Maripat Corr, MD - No relevant financial relationships to disclose
• Beverly K. Johnson, MD, MS - Johnson & Johnson^1,, Consultant TREG⁵
• Bonita Libman, M.D., FACR, FACP - Novartis^2,, Pfizer²
• Sarah B. Lieber, MD - No relevant financial relationships to disclose
• Nancy J. Olsen, MD - Mallinckrodt Pharmaceuticals², IQuity⁵, Cellgene⁹, Pfizer⁹
• Harris Perlman, PhD - No relevant financial relationships to disclose
• Christopher Ritchlin, MD, MPH – UCB^2,5; Abbvie^2,5; Amgen⁵; Janssen⁵; Novartis⁵; BMS⁵; Sanofi⁵
• Richard M. Siegel, MD, PhD - No relevant financial relationships to disclose
• Sharad Lakhanpal, MBBS, MD - Rheumatology Associates³

2019 Division Directors Conference Speaker Disclosures

• Irene Blanco, MD - No relevant financial relationships to disclose
• Leslie J. Crofford, MD - No relevant financial relationships to disclose
• Sonali Parekh Desai, MD - No relevant financial relationships to disclose
• David Karp, MD, PhD - No relevant financial relationships to disclose
• John Rossi, BS, MBA - No relevant financial relationships to disclose
• Luanne Thorndyke, MD, FACP - No relevant financial relationships to disclose

Additional disclosures to be announced

2019 Program Directors Conference Planning Committee Disclosures

• Anne R. Bass, MD - Fidelity⁵; ABIM⁶
• Anisha Dua, MD, MPH - Chemocentryx²
• Kenneth S. O’Rourke, MD - ABIM⁹
• Guillermo Quiceno, MD - Abbvie²
• Rebecca E. Sadun, MD, PhD - No relevant financial relationships to disclose
• Phillip Seo, MD- Genentech⁵; BMS⁵
• Karina D Torralba, MD, MACM, RhMSUS, CCD - Pfizer⁵; Exagen⁵; GSK⁵
• Tracey B. Wright, MD - No relevant financial relationships to disclose
• Gary Firestein, MD - Ignyta^1, Sialix¹, Eli Lilly², NIH², Janssen², Gilead², RRF², UCSD³, Case Western⁵, UpToDate⁷, Elsevier⁷
• Janet Bahr, NP - Abbive⁹
• Gregory Taylor, MSW - No relevant financial relationships to disclose
• Lisa Criscione-Schreiber, MD - Pfizer², National Comprehensive Cancer Center²
• Mark Hwang, MD - No relevant financial relationships to disclose

2019 Program Directors Conference Speaker Disclosures

• Melver Anderson, MD, FACP - No relevant financial relationships to disclose
• Amy Cannella, MD - No relevant financial relationships to disclose
• Lisa G. Criscione-Schreiber, MD - No relevant financial relationships to disclose
• Anisha Dua, MD – ACGME Subspecialty Milestones Workgroup⁶
• Elizabeth Ferucci, MD - No relevant financial relationships to disclose
• Carol Langford, MD, MHS, FACP - No relevant financial relationships to disclose
• Rebecca Sadun, MD - No relevant financial relationships to disclose
• Tracey Wright, MD - No relevant financial relationships to disclose

Additional disclosures to be announced